Table 4.
Dose escalation based on the normal liver effective volume and desired normal liver LKB NTCP for all 20 patients (standard deviation in parentheses)
| 1% NTCP |
5% NTCP |
10% NTCP |
||||
|---|---|---|---|---|---|---|
| MTD (Gy) | BED (Gy) | MTD (Gy) | BED (Gy) | MTD (Gy) | BED (Gy) | |
| cVMAT | 76.80a (27.6) | 170.40a (97.8) | 85.51a (30.7) | 202.70a (117.6) | 90.14a (32.4) | 220.94a (129.0) |
| nVMAT | 80.63a (37.7) | 198.32 (177.7) | 89.76a (41.6) | 236.78 (215.5) | 94.65a (43.8) | 258.67 (237.4) |
| 4π | 91.98 (36.2) | 235.80 (164.8) | 102.43 (40.3) | 281.91 (199.8) | 107.99 (42.5) | 308.08 (219.8) |
cVMAT, coplanar volumetric modulated arc therapy; NTCP, normal tissue complication probability; LKB, Lyman-Kutcher-Burman; MTD, maximum tolerated dose; nVMAT, noncoplanar volumetric modulated arc therapy.
a
Significantly different from 4π plans with P < .05 (paired, 2-tailed t test).